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DNA Sequencing Resolves 




This chapter focuses on the mandatory requirement of DNA sequencing 
approaches for genetic diagnosis and recurrence prevention of inherited diseases. 
Sequencing the DNA and coded transcripts has intensely promoted our understand-
ing of functional genomics and the fundamental importance of non-coding genomic 
sequences in causing heritable diseases, when mutated. Though Sanger sequencing, 
the first employed approach in identifying genetic mutations has been replaced nowa-
days in many laboratories with the highly robust massive parallel sequencing tech-
niques, “Sanger” remains vital in countries with limited resources and also of essential 
importance in validating the results of large scale sequencing technologies. Next 
generation sequencing (NGS) enabled the parallel sequencing of the whole exome 
(WES) and whole genome (WGS) regions of human genome and has revolutionized 
the field of genetic and genomic research in human. WES and WGS have facilitated 
the identification of the role of previously unrecognized genes in causing neurologic 
phenotypes, brain structural malformation, and resolved the causal genes in puzzling 
and misdiagnosed genetic phenotypes. Role of fusion genes and non-coding RNA in 
causing neurogenetic recessive diseases has been uncovered by the application of NGS 
platforms, published examples are presented in this chapter. Extensive phenotypic 
variability that retained patients either as misdiagnosed or undiagnosed cases for 
years has been correctly diagnosed through NGS research applications.
Keywords: DNA sequencing in human genetic disorders, NGS platforms in  
rare diseases, leukodystrophies, neuromuscular disorders, muscle dystrophy,  
non-coding genetic mutation, puzzling phenotypes, NGS, WES, WGS
1. Introduction
Since the significant discovery made by Watson and Crick [1] delineating the DNA 
double helical structure of alternate units (nucleotides) composed of deoxyribose 
sugar phosphate backbone and nitrogen bases pyrimidines (Cytosine, C and Thiamine, 
T) and purines (Adenine, A and Guanine, G). And the following crucial findings, 
Chargaff’s rules [2] informing that the quantity of nitrogen bases differs in between 
species and the numbers of A equal to T, same for C and G [concluding the pairing 
status), the field of genetics, genomics, and hereditary is magnificently progressed.
The biology of the genetic code “central dogma” describes the flow of heritable 
genetic information from the nuclear DNA through the transcription process into 
the mRNA that is further translated into proteins or families of proteins. Central 
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dogma of noncoding regions of DNA has also its influences on the stability of 
mRNA, Exon-intron splicing machinery, and translational efficiency [3–6].
The order (sequence) of nucleotides within a known or yet undiscovered set of 
genes is the first check point that dictates the coded messenger message and translated 
proteins. DNA-regulatory sequences including promoters, un-translated regions, 
DNA-methylation related (epigenetic and posttranscriptional splicing modifications) 
interactively play in defining the transcriptome and proteome expression profiles in 
different tissues of the body. Newly developed sequencing technologies have enabled 
the discovery of these regulatory and expression-modifier sequences [7–9].
Changes in the sequence of DNA-nucleotides located at the coding, non-coding, or 
splicing regions of the genome are anticipated to amend, in different ways, the genetic 
message as well as properties of the coded proteins and hence its functions in the cell.
These sequence variations are either inherited (passing from a generation to 
the next through the germline’s cells; ovum/sperm) or spontaneous (de novo) in 
a subject germ cells. Spontaneous mutations will be further potentially inherited, 
mostly in a dominant pattern, through the subject’s descent when his/her reproduc-
tion ability is not affected by the mutation. Changes (polymorphic variations or 
disease underlying mutations) in the DNA sequence may arise through base substi-
tution, small insertion or deletion of bases, structural variations (large deletions or 
complex rearrangements), dynamic mutations (expansion of repetitive elements of 
the genome). DNA, cDNA, or RNA sequencing tools are the evidence based inves-
tigations that help us as scientists or physicians to identify or “see in Sanger’s chart” 
these nucleotide changes and accurately allocate its genomic position [10, 11].
Monogenetic (Mendelian) disorders caused by single gene defect(s) are regularly 
counted under rare (orphan) diseases. Population with high rate of consanguineous 
marriages described to have extended multiple generational families that harbor rare 
monogenetic diseases. The single gene defect can occur on the two copies (alleles) 
of a gene (homozygous mutant) or on one allele only (heterozygous). Inheritance of 
Mendelian disorders may be autosomal recessive (the two alleles of an autosomal gene 
should carry the causative mutation to produce the disease phenotype), dominant (one 
mutant allele will be enough to cause the genetic disease), or X-linked (the mutant 
gene is located on the X chromosome) with the disease transmission occurring mostly 
through the females who are obligate carrier of the X-linked mutation [12, 13].
Monogenetic diseases may affect various body systems; cardiovascular, central 
nervous, peripheral nerves, endocrine, renal, or pulmonary, etc. The clinical 
phenotypic spectrum of the different distinct categories of these diseases is likely 
heterogeneous or overlapping which harden the clinicians’ decision in making a 
definitive diagnosis. Academic studies in the field of human genetic diseases as well 
as diagnostics has been complicated for a long period of time by the remarkable 
clinical and genetic heterogeneity that were evident for the subgroups of a bunch 
of familial recurrent diseases involving: congenital muscle dystrophies, limb girdle 
muscle dystrophies, cortical brain malformation, hereditary spastic paraplegias, 
hereditary sensory neuropathies, neurodevelopmental, or others. With the evolving 
NGS technologies progress and discovery has been promptly started.
DNA and cDNA high throughput and validation sequencing tools are funda-
mental approaches that should be implemented in laboratories to reach a correct 
genetic diagnosis and provide accurate genetic counseling for rare heritable 
diseases. Genetic diseases may remain for decades undiagnosed or incorrectly 
managed when sequencing technologies are either not available or not accessible to 
patients due to its high cost. Genes and mutations identification in patients services 
all family members; siblings, cousins, nephews, or other relatives allowing carrier 
detection, premarital planning when first cousin or relative marriage is considered, 
prenatal diagnosis or preimplantation genetics. These sequencing outcomes mark 
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the long term goal of reducing the occurrence or recurrence of genetic disorders in 
the community achievable.
Discovery of new genes and novel genetic “mutations/etiologies” for rare dis-
eases, has exposed the basis of genetic heterogeneity, increased depth of genomic 
investigations and been intensely empowered, starting 2005, by the emerged 
technologies of next generation sequencing (NGS) that enabled the massive parallel 
sequencing (MPS) of millions of DNA or RNA nucleotides at a time [11, 14].
Whole Exome Sequencing (WES), one of the NGS platforms, grew into a 
widely used genetic diagnostic test in certified diagnostic labs over the world as 
well as a research tool in academic studies. WES targets the variants located in the 
coding regions and splicing boundaries of genes simultaneously at a time. The 
protein coding genes have been estimated to constitute ~2% of the human genome. 
Though WES is a powerful tool for the identification of underlying genetic defect in 
Mendelian disorders, obviously it lacks the capacity to detect non-coding or regula-
tory disease causing genetic variations [15–18].
Whole Genome Sequencing (WGS), most extensive NGS’ platform, has the capac-
ity to interrogate the whole genome of a subject; the promoters, the un-translated 
upstream and downstream genomic ends, intragenic and intergenic regions in addi-
tion to the coding and splicing parts. Its applications in monogenetic diseases are still 
mostly at the level academic research. Its value in discovering new causal roles of pre-
viously unrecognized genes in rare inherited diseases came from its nature in detecting 
non-coding, regulatory and large structural variations arise in subjects’ genome [19].
Advances in NGS wet lab methodologies, improvements in informatics pipelines 
(read alignment, variants call), and the huge released data annotation and analysis 
platforms lead the new genes discovery, the identification of new etiologies for rare 
diseases, and new cellular mechanisms contributing genetic syndromes and disor-
ders. The better understanding of molecular biology of gene’s mutation constitutes 
the essentials for new therapeutics [20].
In this chapter we shed the light on live recent examples demonstrating the role 
of DNA sequencing tools in gene discovery and in resolving the dilemma of certain 
genetic phenotypes that were undiagnosed for years.
2.  Sanger sequencing
2.1 Advances in diagnostics and research of Monogenetic diseases
To late nineties Sanger sequencing (Chain Terminator Method) was the tool we 
used to use both in service and research to identify gene mutations or recognize 
polymorphic sequence variations in particular gene(s). Sanger Sequence is named 
after Frederick Sanger and his colleagues who had developed the method in late 
seventies [21, 22]. This sequencing method enabled the identification of nucleotides 
sequence in a single DNA or RNA amplified fragments and hence the changes 
(variations) from the reference genomes. Sanger Sequencing was highly applicable 
in diagnostics when a particular gene or few alternative genes are in question.
2.2  Demonstrative example from author’s experience: a well-defined genetic 
phenotype with two alternative claimed causative genes confirmed true by 
Sanger sequencing
Here, we show the value of Sanger sequencing in resolving, in a fairly good turn-
around time, the genetic defect in a group of patients with a phenotype of abnormal 
cerebral white matter associated with subcortical cysts. The leukodystrophies are a 
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group of diseases, collectively characterized by primarily white matter involvements 
at variable degrees of severity ranged from a change in signal intensity, on brain 
images, to cystic cavitation or vanishing of the brain white matter contents [23, 24]. 
This group of diseases is genetically heterogeneous, however with a good clinical 
history, examination and high resolution brain imaging, a differential diagnosis 
can be set and Sanger sequencing can be applied for the few differential genes. The 
association of distinctive clinical features of macrocephaly (large sized head) detected 
since birth or shortly thereafter, motor developmental delay, seizures and ataxia 
precipitated by trauma as well as brain images of diffusely swollen white matter with 
the very characteristic finding of subcortical cysts preferentially occurring in brain 
temporal or frontoparietal lobes (Figure 1) suggested a clinical diagnosis of mega-
lencephalic leukoencephalopathy (MLC), an autosomal recessive disease [OMIM # 
604004]. A long list of metabolic disorders can be listed for a differential diagnosis.
In 75% of these patients, MLC1 gene’s mutations are causal for the disease 
phenotype, whereas in ~20% of cases it is another gene, the HEPACAM/Glia-CAM 
that contributes the MLC phenotype. Both MLC1 and Glia-CAM are of a reasonable 
coding regions’ size. Application of direct Sanger sequencing had helped several 
of such patients to get a solid genetic diagnosis of their diseases and allowed their 
families to use the Sanger sequencing results in performing premarital counseling 
and preventive measures through the carrier detection and prenatal diagnosis. Thus 
in cases feature a rather defined phenotype, average sized coding region of genes 
are in claim, and few alternative candidate causative genes, application of Sanger 
sequencing empowers the genetic diagnosis in a fair short turnaround time and 
makes the disease primary prevention quite possible [25].
2.3 Immunohistochemistry-guided Sanger sequencing
In some other diseases due to a known contributing family of proteins coded by a 
subset of genes, the roundabout time may be quite consuming to resolve the specific 
causal gene and hence Sanger sequencing may not be the suitable diagnostic tool par-
ticularly when there is a large flow of samples. A good such example is the Limb Girdle 
muscle dystrophies (LGMDs) which constitute a large group of progressive muscle 
weakness and wasting. Each of the several main groups of LGMD possesses a list of 
several subtypes caused by genetic mutations in many of muscle proteins related genes.
Muscle biopsy (a specimen of muscle fibers) used in immunohistochemical 
staining is an invasive diagnostic approach applied in patients with LGMDs aiming 
to detect the specific missing (deficient) muscle protein, secondary to gene’s altera-
tion using mono- or poly-clonal antibodies.
Sarcoglycanopathies is a known genetic group of LGMDs. It is comprised of a 
family of four proteins forming four subgroups of sarcoglycanopthies; alpha, beta, 
gamma, and delta annotated according to the encoded protein and the correspond-
ing gene [26].
The antibodies implemented in the immunohistochemistry procedure are antici-
pated to have the capacity to confirm the diagnosis of sarcoglycanopathy-LGMD and 
the level of the specific protein expression in the muscles, or in the best case scenario 
may also suggest the specific type of deficient sarcoglycan, whether alpha or beta, etc. 
However, in order to confidently determine which of the four sarcoglycan genes, α, β, 
Ƴ, or delta harbors a heritable causative pathogenic mutation, gene sequencing should 
follow the immunohistochemistry. In such cases, Sanger sequencing guided by the 
immunohistochemistry results possibly will be a valuable diagnostic approach in areas 
of limited resources, particularly in extended families with multiple affected subjects 
across successive generations (Figure 2). However, many of the times this is not the 
case since the antibodies cross react to its different proteins subtypes. In such situation, 
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though the time required to interrogate multiple related genes, each separately and 
release the results may be relatively long, however the sequencing outcomes’ signifi-
cance in disease’s prevention and recurrence worth the time and efforts.
Figure 1. 
Brain magnetic resonance imaging (MRI) in Egyptian patients with MLC1 mutations [25]. Permission 
obtained from the copyright owner. Images are of different MLC patients captured at ages between 2 and 
3 years old. Images T1-weighted sagittal (A and C), coronal (B), and axial (D): show extensive large vacuoles 
(A), widespread cystic changes involving frontal, temporal, most of the parietal, and occipital white matter 
(B), diffusely abnormal and swollen cerebral white matter (C and D). Cystic changes in frontal, parietal (C), 
and temporal subcortical regions (D). Images T1 weighted (E and F): display diffusely abnormal and swollen 
cerebral, subcortical, and periventricular, white matter. Cystic changes are visible in the frontal lobes (F). 
Axial T2 image at high level (G) demonstrates cystic changes (vacuolation) affecting different brain cortical 
regions. Sagittal T1 image of normal brain is included to support perception of the striking differences.
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2.4 Challenges for the diagnostic application of Sanger sequencing
Genes of extensively large coding regions like the FBN1, Titin, dystrophin, and 
many others constitute a challenge to use Sanger direct sequencing as a robust tool 
to characterize the underlying mutations. As a kind of solution, numerous commer-
cial labs are limiting their molecular diagnostic service to specific gene’s mutations’ 
hot spots reported in the populations, when applicable. However, this approach is of 
a limited value when the case harbors a new or rare gene mutation.
In rather complex or non-specific clinical genetic presentations that are either 
of un-determined causative genes or of negative gene panel’s results for a particular 
group of diseases, the Sanger sequencing remains unaccommodating.
The evolving roles of non-coding RNA and regulatory sequences alterations 
in causing heritable genetic diseases toughen the value of Sanger sequencing in 
diagnostics and human genetic research academic studies.
For all of these essentials new accommodating approaches were in need to 
satisfy the health care providers’ goals to better serve patients with genetic diseases 
and the researchers need toward discovery of new genes and new etiologies for 
undiagnosed or misdiagnosed genetic disorders.
Targeted genes panel is a designed approach aiming to collectively sequencing a 
group of genes of a known causative relation to a particular inherited genetic disease 
or a group of closely related diseases. Examples involve panels for Limb girdle muscle 
dystrophy, hereditary spastic paraplegias (HSPs), inherited deafness, etc. This 
approach essentially and basically requires a continuous update of the designed panel 
to involve newly discovered genes aiming at avoiding false negative results. HSPs are a 
large group of diseases characterized by progressive lower limb spasticity, raised heal 
Figure 2. 
Extended pedigree with autosomal recessive LGMD alpha-Sarcoglycanopathy. Diagrammatic representation 
of sarcoglycans complex. The pedigree displayed the effect of consanguineous marriages in producing multiple 
generations with AR-limb girdle muscle dystrophy (LGMD): subtype alpha sarcoglycan that was confirmed 
only on DNA sequencing. Immunohistochemistry to the core family reported delta sarcoglycan [cross reactivity 
pitfall]. The diagram demonstrates the sarcoglycans complex (alpha, beta, gamma, and delta), a family 
of skeletal muscle sarcolemma proteins that are connected to the extracellular matrix through the alpha 
dystroglycans (αDG) which connects to the intracellular dystrophin and actin proteins (muscle cytoskeleton) 
via βDG forming the dystrophin-glycoprotein complex (DGC).
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(tip toes) gait and associated in its complex phenotype with brain images abnormali-
ties, developmental delay, ataxia, and other features. The list for HSPs associated 
gene defects is huge involving around 80 genes and continues to expand further [27]. 
Commercial HSP gene’s panel are offered by various diagnostic laboratories, however 
pitfalls of negative results that falsely decline the diagnosis of HSPs is not uncommon.
Academic studies discover newly characterized HSP related genes yearly; this 
has to be regularly updating the diagnostic market. A proper alternative tool will be 
one of the cut edge NGS technologies.
3. Next Generation Sequencing (NGS)
3.1 NGS role in mapping genes and mutations to monogenetic diseases’ phenotypes
WES and WGS yield a high throughput set of data. Of the interpretation 
process, these raw sequencing data/reads should be aligned to human reference 
nuclear genome. Differences between the subjects’ sequencing reads and the refer-
ence genome are annotated as “variations” which may be counted either as common 
“polymorphic” or rare variants. The file contains all annotated variants of subject’s 
sample is designated as the variants calling files (VCF).
The NGS’ chemistry and nucleotide capture efficiency, depth of sequencing 
coverage, as well as bioinformatics pipelines employed in calling the variants of 
subjects’ genome including the quality of mapping/alignment to the reference 
genome govern the potentials of the NGS’ output [VCFs] in genes identification 
[28–30].
The key challenge in NGS data analysis is to identify the disease causal variants 
against the tremendous number of variants that are present at a low/rare frequency 
in genome or annotated, in-silico, as deleterious/pathogenic. Variants prioritization 
is the protocol employed to select the most potential disease causing variants. The 
diagram below (Figure 3) represents the number of variants originally called in 
WGS data of a subject and the filters sequentially applied aiming to highlight the 
most potential candidate disease related variants.
3.2  Gene discovery: identification of genes underlying a worldwide known 
clinical diagnosis
Kabuki syndrome (KS), OMIM # 147920 is a developmental, musculoskeletal, 
and intellectual disability with distinctive facial features genetic syndrome. This 
syndrome was first described, clinically, in families from Japan in 1981 [31] then 
described worldwide in patients from different ethnic groups. Intensive research has 
been made using the emerged high throughput sequencing technology to identify 
the KS causative gene, however unsuccessfully. The sporadic nature of KS (affected 
patients had negative family history and unaffected parent) harden the path of 
gene identification. The first Kabuki-associated gene (Lysine methyltransferase 2D, 
KMT2D, originally named as MLL2, a gene that regulates the expression of several 
downstream targets) was discovered only by late 2010 [32] along with the further 
developments made to WES and the process of variants identification and interpre-
tation. KMT2D spontaneous gene mutations were found in over 75% of patients. A 
second X linked functionally related gene lysine demethylase 6A (KDM6A) contrib-
utes 20% of KS cases [33].
This illustrates how it took about 30 years to identify the underlying gene(s) of a 
well-defined inherited genetic phenotype. Though the most modern high through-
put technology was available for quite number of years, however refinement and 
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optimization of variants calling pipeline and variants analysis was recurrently 
visited to evolve into successful gene discovery for KS.
3.3 NGS approach resolves puzzling clinical phenotypes
With the author experience and the clinical examples discussed below we are 
aiming to outline the significance of NGS in driving research’s discovery into clini-
cal implementation and patients care.
Hereditary sensory and autonomic neuropathies, HSANs, are a genetically 
heterogeneous group of diseases, its phenotypic characteristics involve pain sensi-
tivity (sensory loss) with its sequels, decreased sweating (hypohydrosis/autonomic 
function), plus mild motor weakness in a subset of patients [34]. Though the 
mechanism of development of disease pathology is not well understood, however; a 
Figure 3. 
Diagrammatic representation of filters applied in WGS-VCF data analysis. The first line showed number of 
variants and corresponding number of genes called out of WGS in that particular sample. The confidence 
filter reveals the number of variants and corresponding genes passed the quality settings selected for this filter 
including the reads coverage/depth. The common variants filter presents the number of variants and genes after 
exclusion of “common” variants presented in public data base at frequency high ≥1%. The predicted deleterious 
filter has several options in its setting; the user can opt in the parameters wished to be considered in the analysis. 
The genetic filter has alternative options to select pattern of inheritance/transmission; homozygosity vs. 
heterozygosity in cases vs. controls among multiple other options.
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known, short list of underlying genes were characterized and sequenced when the 
unique HSAN phenotype is suspected.
A consanguineous pedigree had two children, a boy and a girl aged 14 and 
10 years respectively displayed a phenotype resembled that of hereditary sensory 
and autonomic neuropathies (HSANs). The clinical presentations characterized by 
two distinct features, sever pain insensitivity associated with hypohydrosis since 
birth along with the sequels of impaired pain sensation and severe aseptic destruc-
tion of large and small joints as well as the vertebrae (Figure 4). The two affected 
siblings had been examined by multiple local and international experts, the clinical 
diagnosis given was a general one describing an immune inflammatory disease (due 
to the joints destruction), however the association of the severely remarkable pain 
insensitivity remained unexplained in the context of immune-inflammation.
WGS revealed, unexpectedly, a homozygous mutation in LIFR. LIFR mutations 
have been associated with Stüve-Wiedemann syndrome (SWS), a lethal autosomal 
recessive skeletal dysplasia that may be associated with mild reduced pain sensation 
in atypical long survivors.
The complexity (overlapping phenotypes) as well as the striking severity of pain 
insensitivity phenotype, which phenocopy HSANs and atypically associated with 
extensive bone destruction challenges the diagnosis. The WGS had resolved this 
case dilemma, provided the family opportunities for preimplantation genetics as 
well as premarital counseling for other family members. Not only had that, but also 
reveals a new mechanism of LIFR’s functional alteration (defective glycosylation 
of the mutant protein) [35]. WGS finding in these cases warrant the attention to 
consider LIFR testing in genetically unresolved phenotypes mimics HSAN.
3.4  NGS maps neurodevelopmental axonal guidance phenotype to a previously 
unrecognized gene
Neurodevelopmental disorders associated with brain malformation are the most 
extensively large group of neurological disorders. This group incorporates a broad 
spectrum of manifestations primarily involving the central nervous system and 
variably associated with motor and/or psychomotor delay, microcephaly, epilepsy, 
specific behavior, abnormal movements, eye symptoms, dysmorphic features, 
or hypotonia. Brain imaging is very helpful for the clinical diagnosis; however it 
remains challenging to reach a firm genetic diagnosis without NGS approaches. 
Each individual disease of this group is of the rare diseases. Some underlying genes 
have been identified and characterized; many others stay unknown or uncharacter-
ized for its role in causing such diseases, waiting further research and discoveries.
We present here such example of a family with three affected siblings, a boy 
and a twin sister born to a consanguineous parent. The clinical phenotype of global 
developmental delay, learning difficulties associated with mild dysmorphism, 
hearing impairment was presented at variable severity between the older boy and the 
two affected female siblings. This clinical phenotype though can be categorized as 
neurodevelopmental disorder, however is very nonspecific. The older boy was given a 
provisional diagnosis of autistic spectrum hyperactivity due to some related features. 
The brain imaging of cortical malformation (polymicrogyria-cobblestone complex), 
central atrophy, and axonal guidance defects were variably shown in the three 
siblings. WGS applied for 8 members of this family (6 siblings: 3 affected and 3 unaf-
fected plus parent) followed by bioinformatic variants analysis and genes functional 
reviews have successfully filtered the SNVs yield and identified a novel nonsense 
mutation in a previously unrecognized gene, Schwanomin-Interacting Protein1 
(SCHIP1) (Figure 5) [36]. SCHIP1 was not previously associated to human neurode-
velopmental disorders or brain malformation. However, mouse studies knocked out 
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schip1 isoforms produced a phenotype of brain axonal guidance defects, similarly to 
that detected in these patients. This gene has multiple isoforms including a fused gene 
(IQCJ-SCHIP1) isoform with variable tissue expression pattern and reported to have 
a role in axonogenesis during brain development. This example demonstrated the 
significant role of massive parallel sequencing approach as well as reviews of studies 
developed in mice with rather similar brain imaging phenotype in characterizing a 
new gene contributing neurodevelopmental-brain malformation phenotype.
Figure 4. 
Phenotypic sequels of severe pain insensitivity, aseptic painless fractures and inflammation of large and 
small joints in patients with LIFR mutation [35]. Permission obtained from the copyright owner. Multiple 
images display: prominent spine kyphoscoliosis. Swollen knee joints; the scar in the left knee is due to surgical 
procedure treating joint’s inflammation. Neuropathic chronic planter ulcerations: extensive and penetrating 
at the right heel, healing at the left big toe; evident hyperkeratosis of surrounding skin. Inflamed and painless 
distal inter-phalangeal joint of the left finger. Kyphoscoliosis, obvious corneal opacity (abnormal white 
band), tongue ulceration, and fissured lips (due to hypohydrosis-dryness) featured the pain insensitivity in the 
younger affected subject. This figure aims to demonstrate how the clinical picture mimics the diseases of pain 
insensitivity however the gene sequencing reveals a different disease category.
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3.5  WGS reveals new non-coding RNA minor splicing component’s machinery 
that maps to a pure congenital cerebellar ataxia phenotype
Hereditary Cerebellar Ataxias (HCAs), the uncoordinated gait and body move-
ments, can be inherited as autosomal dominant or recessive traits or in association 
with other neurological diseases. Hereditary ataxias are due to degeneration of 
cerebellar neurons or spinocerebellar tracts dysfunction [37]. Many several genes, 
its coding regions have been identified as causatives for the HCAs.
The emerging regulatory role of small non-coding RNA is evolving as a new 
mechanism leading human genetic diseases. WGS is particularly relevant to the 
identification of mutations in non-coding regions of the genome. An example, 
the 2nd worldwide of such condition was recently published [38]. In this refer-
enced article, a large interrelated kindred had 6 patients with hereditary ataxias 
of unknown genetic etiology. Delayed speech and developmental milestones, 
congenital hypotonia, dysarthric speech, intention tremor, head nodding, and 
ataxic gait with a falling tendency were the main complains, however at variable 
severity among the affected patients. Brain images support the cerebellar involve-
ments (Figure 6). Clinical diagnosis of an autosomal recessive cerebellar ataxia 
Figure 5. 
NGS maps neurodevelopmental axonal guidance phenotype in a consanguineous family to SCHIP1 [36]. 
Permission obtained from the copyright owner. Images showed (A) the family pedigree, the Sanger sequencing 
validating the nonsense mutation positioned in SCHIP1 and fused IQCJ-SCHIP1 isoform and its recessive 
segregation in family members. (B) Diagrammatic assembly of the IQCJ/SCHIP1 locus (exons illustrated as 
boxes, introns as lines) and the alternatively spliced transcriptional isoforms. The mutation position is marked 
in red. The asterisks indicate a mouse isoform of the human protein.
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was suggested. Genetic investigations involving gene panel test and WES were 
performed; however results came back as negative.
WGS performed, on research basis, for 11 members of two branches of the 
extended family revealed interesting, nevertheless complex result that required 
functional testing to verify the causative gene and the biological impact of the 
Figure 6. 
Brain MRI-sagittal views in normal and patients with ncRNU12 mutations [38]. Permission from the 
copyright owner was obtained. Normal sagittal T1-weighted midline image (A) showing normal cerebellar 
foliation as well as normal brainstem proportions. A normal variant of prominent cisterna magna, the space 
at the posterior fossa (white arrow). Sagittal T2 weighted images (B and C) are of two affected female cousins, 
with variable degrees of clinical severity: pictures displayed dilatation of the cerebellar interfolia spaces 
indicating cerebellar atrophy or hypoplasia, reduction in the superior and inferior vermis’ sizes (arrows). 
Brainstem is moderately affected (smaller in size). Widened CSF spaces around the posterior fossa, 2ndry to 
cerebellar and brain stem atrophy, more obvious in image B.
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genomic mutation. WGS data analysis identified a variant (SNV) that was located 
in the promoter region of a protein coding gene POLDIP3 and fell as well in a small 
nuclear non-coding RNA gene (RNU12) that was transcribed from the opposite 
strand (Figure 7). Interestingly, RNU 12 was reported as a component of the 
U12-minor splicing machinery that functions in splicing of genes containing minor 
introns. Experimental investigations involved quantitative expression of the genes, 
RNA seq, semi-quantitative analysis of retention of minor introns containing genes 
(due to defective splicing machinery) established the causal relation of RNU12 to 
the disease phenotype in this large family. This story underscores the value of WGS 
in uncovering the unrecognized regulatory role of snRNU12 gene in human brain 
development and function. And the value in identifying the molecular gene defect 
in an example of monogenetic diseases that would have been remained uncovered 
when only WES was undertaken. This gene’s result has been used by healthy family 
members in carrier detection, premarital counseling and prenatal diagnosis.
The ages at which patients of this kindred have getting the genetic diagnosis 
of their disease were as of 25 year old (for the female proband), 22 year old for 
her brother, 15 and 10 years old of her sisters (first branch), 19 and 13 years old of 
female siblings of second branch. This highlights how NGS empowered the diagnos-
tic odyssey of monogenetic diseases translating research into clinic improving tar-
geted patients care and prevention of diseases’ recurrence in family and community.
4. Conclusion
Advancement of new therapeutics for genetic diseases is definitely influenced 
by research and technologies that support swift, reliable, and interpretable OMICs 
Figure 7. 
WGS variant identification, Sanger validation, and genomic organization of the region encompassing the 
RNU12 variant [38]. Permission from the copyright owner was obtained. (A) Filters of ingenuity variant analysis 
(IVA) tool used to analyze the WGS data of 11 members of the extended family concluded two variants (one 
pathogenic, the 2nd was a kind of haplotype-linked polymorphism] passed all filters, corresponding to 3 genes, 2 
that were recognized by IVA and a third gene identified by direct inspection of the locus. (B) Sanger sequencing of 
subjects’ DNA validating the single nucleotide substitution on chromosome 22 and its recessive segregation with the 
phenotypes (normal/wild, normal/carrier, patient/mutant). (C) Diagrammatic representation of the chromosome 
22 region, incorporating the variant that maps to the proximal promoter of POLDIP3 and a functional sequence of 
RNU12. POLDIP3 and RNU13 are transcribed from opposite strands (arrows). Multiple functional experiments 
were done and confirmed RNU12 contribution to the phenotype and disease pathomechanism.
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(genomic, transcriptomic and proteomic) research. DNA and RNA sequencing are of 
such technologies that greatly advanced the discoveries in human genetics. However, 
still further improvements of big-data pipeline analysis and functional investigations 
are mandatory to maximize and empower discoveries made by the “Sequencing.”
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